These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 20554708

  • 1. Characterization of and risk factors for the acute-phase response after zoledronic acid.
    Reid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM.
    J Clin Endocrinol Metab; 2010 Sep; 95(9):4380-7. PubMed ID: 20554708
    [Abstract] [Full Text] [Related]

  • 2. Multicenter Study on Observation of Acute-phase Responses After Infusion of Zoledronic Acid 5 mg in Chinese Women with Postmenopausal Osteoporosis.
    Ding Y, Zeng JC, Yin F, Zhang CL, Zhang Y, Li SX, Liu X, Zhang C, Xue QY, Lin H, Pei FX.
    Orthop Surg; 2017 Aug; 9(3):284-289. PubMed ID: 28960821
    [Abstract] [Full Text] [Related]

  • 3. ACUTE PHASE REACTIONS AFTER ZOLEDRONIC ACID INFUSION: PROTECTIVE ROLE OF 25-HYDROXYVITAMIN D AND PREVIOUS ORAL BISPHOSPHONATE THERAPY.
    Crotti C, Watts NB, De Santis M, Ceribelli A, Fabbriciani G, Cavaciocchi F, Marasini B, Selmi C, Massarotti M.
    Endocr Pract; 2018 May; 24(5):405-410. PubMed ID: 29498910
    [Abstract] [Full Text] [Related]

  • 4. Factors associated with acute-phase response of bisphosphonate-naïve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate.
    Popp AW, Senn R, Curkovic I, Senn C, Buffat H, Popp PF, Lippuner K.
    Osteoporos Int; 2017 Jun; 28(6):1995-2002. PubMed ID: 28299378
    [Abstract] [Full Text] [Related]

  • 5. Vitamin D reduces musculoskeletal pain after infusion of zoledronic acid for postmenopausal osteoporosis.
    Catalano A, Morabito N, Atteritano M, Basile G, Cucinotta D, Lasco A.
    Calcif Tissue Int; 2012 Apr; 90(4):279-85. PubMed ID: 22350110
    [Abstract] [Full Text] [Related]

  • 6. Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis.
    John Camm A.
    Clin Ther; 2010 Mar; 32(3):426-36. PubMed ID: 20399982
    [Abstract] [Full Text] [Related]

  • 7. No effect of rosuvastatin in the zoledronate-induced acute-phase response.
    Makras P, Anastasilakis AD, Polyzos SA, Bisbinas I, Sakellariou GT, Papapoulos SE.
    Calcif Tissue Int; 2011 May; 88(5):402-8. PubMed ID: 21305270
    [Abstract] [Full Text] [Related]

  • 8. [Risk factors of acute-phase response following the first-dose administration of zoledronic acid in the treatment of osteoporosis].
    Chen Y, Lu CY, Liu T, Guo YH, Wang Q, Chen DC.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 Jul; 44(4):681-4. PubMed ID: 24059132
    [Abstract] [Full Text] [Related]

  • 9. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB.
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [Abstract] [Full Text] [Related]

  • 10. Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice.
    Sieber P, Lardelli P, Kraenzlin CA, Kraenzlin ME, Meier C.
    Clin Drug Investig; 2013 Feb; 33(2):117-22. PubMed ID: 23184667
    [Abstract] [Full Text] [Related]

  • 11. The role of cytokines and adipocytokines in zoledronate-induced acute phase reaction in postmenopausal women with low bone mass.
    Anastasilakis AD, Polyzos SA, Delaroudis S, Bisbinas I, Sakellariou GT, Gkiomisi A, Papadopoulou E, Gerou S, Makras P.
    Clin Endocrinol (Oxf); 2012 Dec; 77(6):816-22. PubMed ID: 22676573
    [Abstract] [Full Text] [Related]

  • 12. Cytokines and insulin resistance after zoledronic acid-induced acute phase response.
    Kassi G, Papamichael K, Papaioannou G, Giagourta I, Thanou S, Triantaphyllopoulou M, Zapanti E, Papandroulaki F, Ktena V, Karga H.
    Immunol Invest; 2014 Dec; 43(6):544-55. PubMed ID: 24661204
    [Abstract] [Full Text] [Related]

  • 13. Gamma-delta T lymphocytes and 25-hydroxy vitamin D levels as key factors in autoimmunity and inflammation: the case of zoledronic acid-induced acute phase reaction.
    De Santis M, Cavaciocchi F, Ceribelli A, Crotti C, Generali E, Fabbriciani G, Selmi C, Massarotti M.
    Lupus; 2015 Apr; 24(4-5):442-7. PubMed ID: 25801887
    [Abstract] [Full Text] [Related]

  • 14. Effect of single-dose dexamethasone on acute phase response following zoledronic acid: a randomized controlled trial.
    Billington EO, Horne A, Gamble GD, Maslowski K, House M, Reid IR.
    Osteoporos Int; 2017 Jun; 28(6):1867-1874. PubMed ID: 28233020
    [Abstract] [Full Text] [Related]

  • 15. Circulating γδ T cells and the risk of acute-phase response after zoledronic acid administration.
    Rossini M, Adami S, Viapiana O, Ortolani R, Vella A, Fracassi E, Gatti D.
    J Bone Miner Res; 2012 Jan; 27(1):227-30. PubMed ID: 21956654
    [Abstract] [Full Text] [Related]

  • 16. Zoledronic acid: new indication. No therapeutic advantage in postmenopausal osteoporosis.
    Prescrire Int; 2008 Aug; 17(96):143. PubMed ID: 19480098
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.